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This review discusses recent developments in our under-
standing of hepatocyte death receptor signaling and its
mechanistic link to inﬂammation in steatohepatitis. Tumor
necrosis factor-related apoptosis-inducing ligand receptor
activation in hepatocytes during lipotoxicity induces release
of proinﬂammatory extracellular vesicles, which, in turn,
promote proinﬂammatory macrophage activation.
Nonalcoholic fatty liver disease (NAFLD) is becoming a public
health problem worldwide. A subset of patients develop an
inﬂammatory disease, nonalcoholic steatohepatitis (NASH),
characterized by steatosis, hepatocellular death, macro-
phage and neutrophil accumulation, and varying stages of
ﬁbrosis. Hepatocyte cell death triggers the cellular inﬂam-
matory response, therefore reducing cell death may be
salutary in the steatohepatitis disease process. Recently, a
better understanding of hepatocyte apoptosis in NASH has
been obtained and new information regarding other cell
death modes such as necroptosis and pyroptosis has been
reported. Hepatocyte lipotoxicity is often triggered by death
receptors. In addition to causing apoptosis, death receptors
have been shown to mediate proinﬂammatory signaling,
suggesting that apoptosis in this context is not an immuno-
logically silent process. Here,we review recent developments
in our understanding of hepatocyte cell death by death re-
ceptors and itsmechanistic link to inﬂammation inNASH.We
emphasize how proapoptotic signaling by death receptors
may induce the release of proinﬂammatory extracellular
vesicles, thereby recruiting and activating macrophages and
promoting the steatohepatitis process. Potential therapeutic
strategies are discussed based on this evolving information.
(Cell Mol Gastroenterol Hepatol 2015;1:17–27; http://
dx.doi.org/10.1016/j.jcmgh.2014.11.005)containing 3; PUMA, p53 up-regulated modulator of apoptosis; RIP, re-
ceptor-interacting protein kinase; ROCK1, Rho-associated, coiled-coil
containing protein kinase 1; TNF, tumor necrosis factor; TNFR, tumor
necrosis factor receptor; TRAIL, tumornecrosis factor-relatedapoptosis-
inducing ligand; TRAIL-R, tumor necrosis factor-related apoptosis-
inducing ligand receptor; VX-166, (3S)-3-[[(2S)-2-[3-(methox-
ycarbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-
tetraﬂuorophenoxy)pentanoic acid; VX-740, (4S,7S)-N-[(2R,3S)-2-
ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-
dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carbox-
amide; VX-765, (2S)-1-[(2S)-2-[(4-amino-3-chlorobenzoyl)amino]-3,Keywords: Apoptosis; Caspase Inhibitor; Cell Death; Death
Receptors; Exosomes; Extracellular Vesicles; Fibrosis; Inﬂam-
mation; Inﬂammasome; Microvesicles; Necroptosis; Pyroptosis.
onalcoholic fatty liver disease (NAFLD) has become
3-dimethylbutanoyl]-N-[(2R)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-
carboxamide.
© 2015 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2014.11.005Nthe most common chronic liver disease in the
United States and other Western countries. It is estimated
that up to 30% of the Western world’s population is affected
by NAFLD.1 A subset of patients with NAFLD (w10% to
25%) develop nonalcoholic steatohepatitis (NASH), a more
severe form of the disease characterized by hepatocellulardeath, accumulation of inﬂammatory cells, and varying
stages of ﬁbrosis. NASH can further progress to end-stage
liver disease, cirrhosis, and hepatocellular carcinoma.
NASH has become a signiﬁcant public health concern,
confounded by the lack of effective therapies. Thus, there is
an urgent and unmet need for effective treatment that
would parallel patients’ lifestyle modiﬁcations. Insight
regarding the molecular and cellular mechanisms underly-
ing disease development and progression may provide the
impetus for rationale therapeutic strategies.
Cell death is a cardinal feature of NASH, as is accumu-
lation of inﬂammatory cells, especially macrophages and
neutrophils. Although it is widely accepted that cell death
promotes cellular inﬂammation, the mechanistic link be-
tween cell death and hepatic inﬂammation remains enig-
matic. Recent information links death receptor signaling to
cell death in NASH by processes that promote cell-based
inﬂammation. Thus, it is both timely and topical to review
this information and emphasize therapeutic opportunities.Modes of Cell Death
Hepatocyte apoptosis is the predominant cell death
pathway in NASH. In addition, other types of programmed
Figure 1. Modes of cell death. Activation of apoptotic, necroptotic, or pyroptotic signaling pathways leads to cell death. Left
panel: Upon binding of a death ligand, the intracellular domain of a death receptor recruits adaptor proteins such as Fas-
associated protein with death domain (FADD) and pro-caspase 8 to form a signaling platform termed the death-inducing
signaling complex (DISC). Caspase 8 undergoes proteolytic autoactivation, resulting in direct or indirect (via mitochondria)
activation of caspases 3, 6, and 7, which execute the ﬁnal step of cell death. Various stimuli, including endoplasmic reticulum
stress, trigger apoptosis via the intrinsic pathway, where mitochondrial permeabilization is a central event. Release of proapo-
ptotic factors from mitochondria into the cytosol activates caspase 3, 6, and 7 and cell death by apoptosis. Middle panel:
Necroptosis is initiated by death receptors in cells where caspase 8 function is inhibited. Under these conditions, death receptor
activation promotes formation of a necrosome, a signaling complex comprising FADD, receptor-interacting protein kinase 1
(RIP1), and RIP3. This complex induces cell death via mixed lineage kinase domain-like protein (MLKL), and probably other
mediators. Right panel: Pyroptosis is a cell death mode resulting from activation of inﬂammasomes, including NLRP3 inﬂam-
masome. Upon activation, the intracellular receptor NLR family, pyrin domain containing 3 (NLRP3) recruits apoptosis-associated
speck-like protein containing a CARD (ASC) and pro-caspase 1. Cleavage-activated caspase 1 then induces cell death.
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reported. These cell death modes remain largely unexplored
and merit further examination. Cell death modes such as
necrosis and autophagy are not discussed in this review as
they are not triggered by death receptors. These cell bio-
logical processes and their respective roles in liver patho-
biology and steatohepatitis are reviewed elsewhere.2,3Apoptosis
Apoptosis is highly organized cell death process that is
morphologically characterized by cell shrinkage, membrane
blebbing, chromatin condensation, DNA fragmentation, and
formation of apoptotic bodies. Importantly, apoptotic cell
death depends on the activity of caspases, a family of
cysteine-dependent aspartate-speciﬁc proteases. Apoptosis
can be initiated by two fundamental pathways: extrinsic and
intrinsic pathways. The extrinsic pathway is initiated by
death receptors that belong to tumor necrosis factor (TNF)receptor superfamily. Hepatocytes express death receptors
Fas, TNF receptor 1 (TNFR1), and TNF-related apoptosis-
inducing ligand (TRAIL) receptor (TRAIL-R) 1 and 2.
Activation of these receptors leads to formation of a
death-inducing signaling complex (DISC), which consists of
caspase 8 and adaptor proteins, such as Fas-associated
protein with death domain (FADD, Figure 1). In hepato-
cytes, activated caspase 8 cleaves Bid, generating tBid, which
then induces the cytosolic egress of proapoptotic factors
from the intermitochondrial space (eg, cytochrome c).
Downstream of mitochondrial dysfunction, cytochrome c
promotes formation of the apoptosome, which activates
caspase 3, 6, and 7. These effector caspases execute cellular
demolition. In hepatocytes, apoptosis is often initiated by the
death receptor pathway.4
The intrinsic pathway of apoptosis is mediated by mito-
chondrial or lysosomal permeabilization. In addition,
signaling between the endoplasmic reticulum (ER) and
mitochondria can promote apoptosis. The intrinsic pathway of
January 2015 Death Receptor Signaling in NASH 19apoptosis is regulated by proapoptotic and antiapoptotic
members of Bcl-2 family of proteins. Bak and Bax are proap-
optotic proteins, activation of which results in outer mito-
chondrial membrane permeabilization and apoptosis as
previously described. The antiapoptotic proteins of Bcl-2
family, such as Mcl-1 and Bcl-2, can prevent apoptosis by
binding toBak andBax. Other proteins of this family, including
p53 up-regulated modulator of apoptosis (PUMA), Bid, Bim,
Bad, and Noxa, can activate proapoptotic Bax and Bak directly
or indirectly via sequestration of antiapoptotic proteins.
In hepatocytes, there is cross-talk between these two path-
ways as death receptor cell killing often relies on tBid gen-
eration to trigger the mitochondrial cell death pathway.
Necroptosis
Necroptosis refers to a recently discovered cell death
mode that incorporates features of both apoptosis and
necrosis. It shares some molecular machinery with
apoptosis, but the ﬁnal outcome resembles necrosis with
organelle swelling and cellular leakage. Necroptosis occurs
only under conditions when caspase 8 activation is sup-
pressed by inhibition or genetic deletion,5 hence its physi-
ologic context is unclear and highly controversial.
Necroptosis can be triggered by activation of death re-
ceptors, Toll-like receptors, and perhaps other signals,
which leads to an assembly of a large multiprotein signaling
complex termed necrosome (Figure 1). The necrosome
consists of caspase 8, FADD, cellular FLICE/caspase 8–like
inhibitory protein (cFLIP), receptor-interacting protein
(RIP) 1 and RIP3, and via RIP3 activates downstream
effectors of necroptosis, such as mixed lineage kinase
domain-like protein (MLKL). During necroptosis, RIP3
phosphorylates MLKL, which in turn oligomerizes and
translocates to the plasma membrane, causing plasma
membrane permeabilization.6,7 In physiologic conditions,
the complex caspase 8/FADD/cFLIP may act as a suppres-
sor of necroptosis by limiting RIP3 activation.8 Given the
fact that livers of caspase 8/mice are resistant to Fas- and
TNF-a-induced cell death,9,10 it is unlikely that signiﬁcant
necroptosis occurs in hepatocytes.
Pyroptosis
Pyroptosis is another form of programmed cell death,
ﬁrst described in immune cells during antimicrobial re-
sponses.11 Unlike apoptosis, pyroptosis requires activity of
caspase 1, 4, or 5 and, similarly to necrosis, leads to cellular
leakage and release of intracellular content.12,13 Pyroptosis
is initiated by pathogen-associated molecular pattern
interaction with intracellular pattern recognition receptors,
which leads to a formation of the inﬂammasome, a large
intracellular signaling platform.
Several proteins recruited to inﬂammasomes have been
identiﬁed. The best characterized inﬂammasome is a complex
consisting of NLR family, pyrin domain containing 3 (NLRP3),
apoptosis-associated speck-like protein containing a CARD
(ASC), and pro-caspase 1 (Figure 1). Upon complex formation,
activated caspase-1 cleaves inactive precursors of the proin-
ﬂammatory cytokines pro-interleukin 1b (pro-IL-1b)andpro-IL-18 into their active forms IL-1b and IL-18, respec-
tively. The proinﬂammatory signaling of the cytokines can
occur both in infection and sterile inﬂammation. Inﬂamma-
some can also be activated in response to endogenous
damage-associated molecular pattern and perhaps can be
implicated in sterile liver inﬂammation.14 Recently, lipopoly-
saccharide was shown to directly activate caspase 4 and 5
and induce pyroptosis.13 Nevertheless, whether cells can die
via pyroptosis in the absence of microbial infection is unclear.
Lipotoxicity
Hepatocyte lipotoxicity is a cardinal feature of NASH.
Lipotoxicity originates from accumulation of lipid in-
termediates that cause cellular dysfunction and eventually cell
death. During NASH, hepatocytes accumulate triglycerides and
various lipid metabolites, including free cholesterol, ceram-
ides, and free fatty acids (FFA).15 Hepatocytes store most fatty
acids in the form of triglycerides, and recent evidence sug-
gests that fatty acid esteriﬁcation into neutral triglycerides is a
protective mechanism against lipotoxicity.16,17 In contrast,
FFA cause hepatocyte injury and activate speciﬁc signaling
cascades, resulting in hepatocyte apoptosis, which in this
context is referred to as lipoapoptosis. Thus, FFA are
considered a major mediator of hepatocyte lipotoxicity.
Indeed, in NASH there is an increased hepatic inﬂux of FFA as
a consequence of enhanced lipolysis in peripheral adipose
tissue due to insulin resistance.1,18 FFA lipotoxicity in hepa-
tocytes is mediated, in part, by their intracellular metabolite
lysophosphatidyl choline, which was also found to be
increased in the liver of NAFLD patients proportionally to
disease severity.19,20
Lipoapoptosis
Hepatocyte apoptosis is the most common and best-
characterized cell death pathway in NASH. Indeed, hepato-
cyte apoptosis appears to be a cellular mechanism
distinguishing NASH from simple steatosis, and excessive
hepatocyte apoptosis is a pathologic hallmark of NASH.21–23
Moreover, the magnitude of hepatocyte apoptosis correlates
with degree of inﬂammatory activity and stage of ﬁbrosis.22
In vitro, death receptor signaling via TRAIL-R2 has
emerged as a key mechanism of hepatocyte lipoapoptosis
(Figure 2). Treatment of hepatocytes with the toxic satu-
rated FFA palmitate causes reorganization of plasma
membrane domains, allowing clustering and thus ligand-
independent activation of TRAIL-R2, leading to hepatocyte
cell death via caspase 8.24 Recently it has been demon-
strated that persistent ER stress promotes apoptosis via
TRAIL-R2.25 Unmitigated ER stress increases protein levels
of TRAIL-R2 but not other death receptors, leading to
ligand-independent activation of TRAIL-R2 and caspase
8–dependent apoptosis. Because saturated FFA induce ER
stress,26,27 this TRAIL-R2 signaling pathway may also
contribute to palmitate-induced lipoapoptosis. For example,
FFA also induce ER stress and expression of the transcrip-
tion factor CAAT/enhancer-binding homologous protein
(CHOP), which transcriptionally mediates PUMA up-regula-
tion.27 Enhanced PUMA expression is also a feature of
Figure 2. Apoptotic signaling pathways in lipotoxic
hepatocyte. Hepatocyte treatment with the free fatty acid
(FFA) palmitate causes ligand-independent clustering and
activation of tumor necrosis factor (TNF)-related apoptosis-
inducing ligand receptor 2 (TRAIL-R2), resulting in caspase-
dependent cell death. Active caspase 8 cleaves Bid into its
truncated form tBid, which translocates to mitochondria to
promote the release of proapoptotic factors such as cyto-
chrome c. FFA also causes endoplasmic reticulum stress,
which via CAAT/enhancer binding homologous protein
(CHOP) or c-Jun N-terminal kinase (JNK) up-regulates pro-
apoptotic proteins p53 up-regulated modulator of apoptosis
(PUMA) and Bim, and TRAIL-R2. Increased levels of PUMA
and Bim facilitate hepatocyte cell death via the mitochondrial
apoptotic pathway.
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to activate the mitochondrial pathway of cell death. In
addition, FFA increase the expression of proapoptotic pro-
tein Bim via mechanisms dependent on c-Jun N-terminal
kinase (JNK) and FoxO3a, which also may be the result of ER
stress.28,29 Taken together, these data suggest that by
altering plasma and intracellular membranes, toxic lipids
induce the expression and activation of TRAIL-R2, which in
the context of JNK-dependent PUMA and Bim up-regulation
causes cell death. This latter event is likely critical for lip-
oapoptosis as TRAIL-R activation is nontoxic to healthy
hepatocytes but is toxic to steatotic hepatocytes.30,31
In vivo, liver expression of TRAIL-R2 is increased in both
human and experimental NASH, and fatty murine livers are
sensitized to TRAIL-R2-mediated hepatocyte apoptosis.32,33
We have recently explored the role of TRAIL-R in a murine
model of NASH induced by a high fat, fructose, andcholesterol diet.34 In contrast to humans, mice possess only
a single ortholog for both human TRAIL-R1 and TRAIL-R2,
which we here refer to as TRAIL-R. Mice deﬁcient in
TRAIL-R were remarkably protected against all features
of NASH, including steatosis, hepatocyte apoptosis,
macrophage-associated inﬂammation, and ﬁbrosis. The
protective effect against liver inﬂammation was associated
with diminished hepatocyte apoptosis. Thus, TRAIL-R
signaling plays a key role in NASH pathogenesis by pro-
moting hepatocyte apoptosis.
Fas is abundantly expressed in the liver, and its
expression is also increased in NASH.22 The steatotic liver is
greatly susceptible to Fas-mediated hepatocyte apoptosis,
as demonstrated in ob/ob mice or mice fed a high-
carbohydrate diet that were administered anti-Fas
antibody.35,36 It has been reported that in the normal
liver, hepatocyte growth factor receptor (c-Met) binds
directly to Fas, precluding Fas activation. However, this
inhibitory effect was absent in the steatotic liver, facilitating
ligand-dependent activation of Fas and apoptosis.37 Despite
these observations, there are no data implicating Fas in the
pathogenesis of NASH in vivo.
TNFR1 signaling has been also studied in the context
of NAFLD. Liver expression of both TNFR1 and its ligand
TNF-a are increased in NASH.38,39 In hepatocytes, FFA
cause lysosomal destabilization, which results in release of
cathepsin B into the cytosol and enhanced TNF-a expres-
sion. TNF-a may further promote lysosomal permeabiliza-
tion, thus exacerbating liver injury in a feed-forward loop.40
TNF-a is an important mediator of insulin resistance and
appears to be involved in development of steatosis.
TNFR1/ mice are protected against high-carbohydrate
diet–induced steatosis and liver injury.40 Controversial re-
sults were obtained in ob/ob mice where anti-TNF-a ther-
apy improved steatosis, but genetic deletion of both TNF
receptors did not.41,42 The precise role of TNFR1 signaling
in NASH pathogenesis remains controversial.Necroptosis in Nonalcoholic Steatohepatitis
Currently, information regarding necroptosis in NASH is
very limited. RIP3 seems to be expressed at low levels in
healthy human liver as compared with other organs such as
the pancreas.43 On the other hand, RIP3 expression in-
creases at both mRNA and protein levels in the liver of
NASH patients.44,45 An increased hepatocyte RIP3 expres-
sion was detected by immunohistochemistry in human
NASH livers, albeit cholangiocytes stained for RIP3 even
more strongly.45 The role of liver RIP3 in steatohepatitis
was studied in the methionine/choline-deﬁcient (MCD)
diet where RIP3 was increased especially in mice with
conditional deletion of caspase 8 in liver parenchyma
(hepatocytes and cholangiocytes), which conﬁrms the
consent that caspase 8 functions as a potent suppressor
of RIP3.45 RIP3/ mice and double knockout mice caspase
8//Rip3/ were protected against MCD diet-induced
macrophage liver inﬁltration and ﬁbrosis. Caspase 8 dele-
tion in liver parenchymal cells exacerbated the liver injury
in this study.
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data indicate that caspase inhibitors would be detrimental in
NASH? The answer is probably not. For example, the study
discussed above is in sharp contrast to a previous report by
Hatting et al46 where caspase 8 genetic deletion in hepato-
cytes preventedMCD diet-induced liver injury, inﬂammation,
and ﬁbrosis. The inconsistency of these two studies is unclear
and perhaps lies in the genetic models using different pro-
moters for caspase 8 deletion in hepatocytes versus liver
parenchymal cells. Similar to Hatting et al, unpublished data
from our laboratory suggest that hepatocyte-speciﬁc caspase
8/ mice are protected against nutrient excess-induced
NASH. We also note that caspase inhibitors are protective in
animal models of NASH.47,48 Given the composite observa-
tions, it is unlikely that necroptosis contributes to liver injury
and inﬂammation in NASH.
Pyroptosis in Nonalcoholic Steatohepatitis
Can hepatocytes undergo pyroptosis during NASH?
In vivo studies using mice lacking the functional component
of the Nlrp3 inﬂammasome provide an early answer to this
question. Caspase 1/ mice fed a high-fat diet display the
same amount of hepatocellular cell death and no improve-
ment of liver injury, suggesting that the inﬂammasome plays
a marginal role in hepatocyte cell death in this model.49 In
contrast, Nlrp3/ mice were protected against hepatocel-
lular cell death in a NASH model induced by the choline-
deﬁcient amino acid-deﬁned diet.50 Because both studies
used whole-body knockout models, their distinct outcomes
may arise from different effects of the deleted gene in
various liver cell types.
Another piece of evidence that inﬂammasome activation
may lead to increased hepatocellular death by pyroptosis
was provided by a study with transgenic mice expressing
constitutively active Nlrp3.51 However, the whole-body
Nlrp3 hyperactivation precludes physiologic assessment of
inﬂammasome regulation in disease cell types. Although it is
unlikely that pyroptosis causes cell death in the absence of a
pathogen, inﬂammasome activation may be an important
non-cell-death mediator of NASH.
Cell Death as a Driver of Inﬂammation
Cell death and inﬂammation are intricately connected
and can positively regulate each other. In contrast to
necrosis, cell death via apoptosis has been considered as an
immunologically silent process that is intrinsically tolero-
genic, based on the notion that apoptotic cells maintain their
plasma membrane integrity and thus do not release their
intracellular content. However, an increasing body of evi-
dence indicates that apoptotic signaling, especially by death
receptors, may be proinﬂammatory by releasing extracel-
lular vesicles and various chemokines, which may poten-
tially recruit and activate immune cells.
Another outcome of apoptotic cell death may be
secondary necrosis. Failure of efferocytosis, a process by
which apoptotic cells are removed by phagocytic cells, may
lead to a release of intercellular contents into the extracel-
lular milieu, eliciting an inﬂammatory response. Althoughsecondary necrosis in NASH is largely an unexplored phe-
nomenon, it may also represent a possible link between
apoptosis and inﬂammation. Indeed, failure of efferocytosis
has been implicated in the inﬂammatory response contrib-
uting to atherogenesis, another complication of the meta-
bolic syndrome.52
Death Receptor Signaling and Inﬂammation
Death receptor signaling may activate a proinﬂammatory
response directly or indirectly via inducing apoptosis.
TNFR1 signaling results in transcription of a wide spectrum
of genes involved in the inﬂammatory response, such as
proinﬂammatory cytokines, via transcription factor nuclear
factor kappa B (NF-kB).53 Recent observations that certain
cancers and cancer cell lines are resistant to TRAIL-induced
apoptosis led to a notion that TRAIL may activate non-
apoptotic signaling pathways. Such signaling may drive a
proinﬂammatory response via kinase activation.54–56 In the
context of NASH, our in vitro studies with primary mouse
macrophages lacking TRAIL-R have demonstrated that
TRAIL-R is required for NF-kB activation and proin-
ﬂammatory cytokine expression upon palmitate and lipo-
polysaccharide treatment.34
A number of studies in multiple cell types, including
hepatocytes, demonstrate that Fas signaling leads to the
production of IL-8 and monocyte chemotactic protein-1
(MCP-1), chemokines for neutrophils and macrophages,
respectively. Cullen et al57 have demonstrated that pri-
mary hepatocytes secrete a variety of chemokines,
including MCP-1, chemokine (C-C motif) ligand 3, and
chemokine (C-X-C motif) ligand 1, while undergoing
apoptosis upon treatment with an anti-Fas antibody.
Indeed, MCP-1, a potent chemokine for macrophages, was
implicated in NAFLD pathogenesis.58 It remains an open
question as to whether Fas signaling in steatotic hepato-
cytes during NASH promotes cell death and secretion of
chemokines, thereby stimulating proinﬂammatory re-
sponses. It also is not known whether TRAIL-induced cell
death is associated with the same chemokine release as
observed with Fas.
Extracellular Vesicles
Extracellular vesicles are membrane-deﬁned vesicles
secreted by cells to the extracellular environment in a highly
regulated manner. There are three major types of extracel-
lular vesicles categorized as exosomes, microvesicles, and
apoptotic bodies. They are distinguished based on their
cellular origin: exosomes are derived from the endolysoso-
mal pathway, microvesicles bud from the plasma mem-
brane, and apoptotic bodies are formed by blebbing of the
apoptotic cell membrane.59 The size of exosomes and
microvesicles ranges between 40–120 nm and 50–1000 nm,
respectively. Apoptotic bodies are usually more than 500
nm in diameter.
Exosomes and microvesicles have recently emerged as a
new mechanism of a cell-to-cell communication because
they carry lipids, proteins, and various species of RNA that
can trigger a myriad of responses in target cells. Because
Figure 3. Proinﬂammatory feed-forward loop between lipotoxic hepatocytes and activated macrophages. The illus-
tration depicts the circular feed-forward relationship between hepatocyte lipotoxicity and inﬂammation during nonalcoholic
steatohepatitis (NASH). Lipotoxicity induces the release of extracellular vesicles from hepatocytes. These can be engulfed by
hepatic resident and recruited macrophages, causing macrophage activation. Activated macrophages increase the expression
of death receptor ligands such as Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL), and proinﬂammatory
cytokines such as tumor necrosis factor a (TNF-a), which can cause further hepatocyte apoptosis and exacerbation of
inﬂammation. This vicious circle may be interrupted by several therapeutic strategies. IL-1b, interleukin-1b; ROCK1, Rho-
associated, coiled-coil containing protein kinase 1.
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interactions between multiple cell types, extracellular vesi-
cles likely are mediators of this intercellular communication.
Phagocytosis of hepatocyte-derived apoptotic bodies by
Kupffer cells potently increases expression of TNF-a, TRAIL,
and Fas ligand (FasL).60 These death receptor ligands
induce further hepatocyte apoptosis, which can precipitate
liver inﬂammation and ﬁbrosis.
It has been demonstrated that palmitate-treated hepa-
tocytes release proangiogenic microvesicles.61 The effect of
these microvesicles depends on their internalization into
endothelial cells via vanin-1, a protein expressed on these
microvesicles. Our unpublished data indicate that lipotoxic
hepatocytes release extracellular vesicles that induce
macrophage migration and activation. Importantly, the
release of these vesicles occurs before the onset of
apoptosis, indicating that these vesicles are not apoptotic
bodies. Similarly, Bretz et al62 reported that exosomes from
body ﬂuids such as liver cirrhosis ascites can induce a
proinﬂammatory phenotype in monocytes. Collectively,
these data indicate that extracellular vesicles contain func-
tional mediators of inﬂammatory response.The extracellular vesicles may carry various cytokines,
chemokines, and micro-RNA, and which cargo mediates
inﬂammation needs to be determined by future studies.
Currently, our knowledge of the role of extracellular vesicles
in NASH is limited, but lipotoxic hepatocyte-derived extra-
cellular vesicles might be a potential additional link between
hepatocellular injury and inﬂammation in NASH (Figure 3).
Nonalcoholic Steatohepatitis and
Inﬂammation
Liver inﬂammation in NASH is orchestrated by multiple
intricate mechanisms, and its complex nature is not
completely understood. Cell death elicits inﬂammation by
cells of the innate immune system. Indeed, these are the cell
types that have been implicated in NASH pathogenesis,
macrophages, and neutrophils.
Cell Types Involved
Healthy livers encompass many types of immune cells,
such as resident macrophages (Kupffer cells), natural killer
(NK) cells, and natural killer T (NKT) cells.63 Chronic
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feature of NASH. Several lines of evidence suggest that
Kupffer cells and inﬁltrating macrophages/monocytes play
a cardinal role in NASH pathogenesis. Indeed, macrophage
accumulation in the human liver correlates with the severity
of histologic activity in NASH.64
During NASH, Kupffer cells acquire a proinﬂammatory
phenotype and secrete multiple cytokines and chemokines.
Secreted chemokines, such as IL-8 and MCP-1, which may
also originate from apoptotic hepatocytes,57 recruit neu-
trophils and cells of monocyte/macrophage lineage to the
liver, further accentuating the liver inﬂammation. Activated
macrophages express death receptor ligands and secrete
proﬁbrogenic factors, which further exacerbates the hepa-
tocellular injury and induces liver ﬁbrogenesis in a feed-
forward loop. The importance of macrophages in NASH
pathogenesis is highlighted by studies where the depletion
of Kupffer cells or inhibition of macrophage inﬂux into the
liver prevented hepatic inﬂammation and ﬁbrosis in murine
models of NASH.65,66
Beside macrophages, other immune cells were studied in
NASH pathogenesis. NKT cells appear to be depleted from
the liver during simple steatosis, but they start to accumu-
late with the progression toward NASH.67–71 In sterile liver
injury, two different subtypes of NKT cells appear to have
distinct functions. Recent evidence suggests that type I NKT
cells, which express semi-invariant T-cell receptor, may
promote liver inﬂammation, whereas type II NKT cells,
characterized by more diverse T-cell receptors, may have a
protective role against liver injury.72 Little is known about
the role of dendritic cells in NASH, but it appears that they
exert anti-inﬂammatory and antiﬁbrotic effects in preclinical
models.73,74
Inﬂammatory cells, which express ligands of the death
receptors, may also enhance hepatocyte apoptosis. FasL and
TRAIL can be found on NK cells, NKT cells, and macro-
phages. Given the fact that hepatocyte apoptotic bodies
induce expression of death receptor ligands in Kupffer
cells,60 hepatocyte apoptosis in NASH may be involved in a
feed-forward apoptotic pathway, further exacerbating liver
injury.Inﬂammation as a Mediator of Fibrosis
Fibrosis is the most nefarious consequence of continuous
liver injury and inﬂammation. Progressive ﬁbrosis may
result in cirrhosis, portal hypertension, liver failure, and
hepatocellular carcinoma. It is now well recognized that
chronic inﬂammation is the main driving force for ﬁbro-
genesis in NASH.75,76 Hepatic stellate cells (HSC) and their
production of extracellular matrix have a central role in
NASH-related ﬁbrogenesis. Activated Kupffer cells, inﬁl-
trating macrophages/monocytes, and injured hepatocytes
release cytokines and various proﬁbrogenic factors, such as
platelet-derived growth factor and transforming growth
factor-b1, thereby activating HSC and changing their
phenotype into myoﬁbroblast-like cells.
Interesting concepts have emerged that suggest that
hepatocyte lipotoxicity and cell death can contribute toﬁbrogenesis via extracellular vesicles. We have demon-
strated that engulfment of hepatocyte apoptotic bodies by
HSC increases expression of proﬁbrogenic genes, suggesting
that the cells underwent proﬁbrogenic activation.77 A
similar effect was also observed when HSC were incubated
with isolated microvesicles released from lipotoxic hepato-
cytes.78 Hence, cell death drives hepatic ﬁbrosis indirectly
via inﬂammation and perhaps directly by vesicle-mediated
cell-to-cell communication (hepatocyte/ stellate cell).
Therapeutic Strategies
Caspase Inhibition
Caspase activation has been well documented in both
human and preclinical NASH. Mice lacking caspase 3 and
caspase 8 are protected against diet-induced NASH.46,79
Thus, inhibition of hepatocyte apoptosis via caspase inhi-
bition is a mechanistically attractive target for pharmaco-
therapy for NASH. Moreover, pan-caspase inhibitors may
also inhibit proinﬂammatory caspases such as caspase 1.
Small-molecule caspase inhibitors have been re-
cently developed to circumvent the unfavorable pharmaco-
kinetics of the original peptide-based inhibitors. The
pan-caspase inhibitor IDN-6556 [(3S)-3-[[(2S)-2-[[2-(2-tert-
butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-
(2,3,5,6-tetraﬂuorophenoxy)pentanoic acid] was able to
decrease ﬁbrosis in association with decreased hepatocyte
apoptosis in a model of liver injury leading to ﬁbrosis.80 The
pan-caspase inhibitors IDN-6556 and VX-166 [(3S)-3-[[(2S)-
2-[3-(methoxycarbonylamino)-2-oxopyridin-1-yl]butanoyl]
amino]-4-oxo-5-(2,3,5,6-tetraﬂuorophenoxy)pentanoic acid]
decreased liver injury, inﬂammation, and ﬁbrosis in murine
models of NASH.47,48,81 A recent phase 2 clinical trial
concluded that GS-9450 [(5R)-N-[(2S,3S)-2-(ﬂuoromethyl)-
2-hydroxy-5-oxooxolan-3-yl]-3-isoquinolin-8-yl-5-propan-
2-yl-4H-1,2-oxazole-5-carboxamide] therapy improved liver
injury in a dose-dependent manner in patients with NASH.82
However, the development of this drug may be hampered
due to safety concerns that were raised in another clinical
trial with this agent.
To date, the effect of caspase inhibitors on NASH-
associated inﬂammation and ﬁbrosis has not been evalu-
ated in humans. Given the promising results, a therapeutic
approach based on caspase inhibition warrants more
clinical trials in human NASH.
Interleukin-1b Inhibition
IL-1b, a cytokine generated by inﬂammasome activation,
initiates inﬂammatory cascades and the production of a
number of other proinﬂammatory mediators. Increased
hepatic levels of IL-1b have been detected in preclinical
models of NASH.49,83,84 The role of IL-1b in NASH has been
highlighted by studies using mice lacking genes important
for IL-1b production or signaling. For example, Il-1b/, Il-1
receptor/, Nlrp3/, and caspase 1/ mice were pro-
tected against diet-induced NASH.49,84–86
IL-1b and its receptor can be targeted pharmacologi-
cally by multiple approaches. Human recombinant IL-1
receptor antagonist (anakinra), anti-IL-1b antibody
24 Hirsova and Gores Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1(CDP-484), IL-1 trap, and soluble IL-1 receptor II are bio-
logic agents that target IL-1b neutralization.87 The pro-
duction of IL-1b can also be diminished by caspase 1
inhibition. The small-molecule caspase 1–speciﬁc in-
hibitors VX-765 [(2S)-1-[(2S)-2-[(4-amino-3-chloroben-
zoyl)amino]-3,3-dimethylbutanoyl]-N-[(2R)-2-ethoxy-5-ox-
ooxolan-3-yl]pyrrolidine-2-carboxamide] and VX-740 [(4S,
7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-
1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-
pyridazino[1,2-a]diazepine-4-carboxamide] are safe for use
in humans. Collectively, given the encouraging preclinical
data and availability of experimental therapeutics, IL-1b
inhibition appears to be a potential target for NASH therapy.
Chemokine-Targeted Therapy
Chemokines have a central role in the recruitment of
macrophages/monocytes to the liver during NASH. The
cellular source of chemokines is not only activated Kupffer
cells but also epithelial cells undergoing apoptosis or
secreting chemokine-bearing extracellular vesicles. For
example, MCP-1 and its receptor CCR2 (C-C chemokine
receptor type 2) have emerged as potential targets for
NASH.58 Indeed, a CCR2 small-molecule inhibitor
remarkably prevented hepatic inﬂammation and ﬁbrosis
in preclinical NASH.65 Thus, targeting the chemokine
signaling pathways may be a therapeutic approach for
NASH.
Rho-Associated Kinase 1 Inhibition
In our recent study, we identiﬁed rho-associated kinase
1 (ROCK1) as a key kinase involved in lipotoxicity-induced
extracellular vesicle release (manuscript in preparation).
Genetic deletion or pharmacologic inhibition of ROCK1
signiﬁcantly decreases extracellular vesicle release from
hepatocyte in vitro. We also tested the effect of a ROCK1
inhibitor in a murine model of NASH induced by nutrient
excess. Similarly to the in vitro data, the ROCK1
inhibitor fasudil [5-(1,4-diazepan-1-ylsulfonyl)isoquinoline]
decreased diet-induced increases in serum extracellular
vesicles. ROCK1 inhibition in this model also prevented
hepatocellular injury and decreased macrophage-associated
inﬂammation. Moreover, fasudil is approved for use in Japan
for the treatment of cerebral vasospasm. Hence, its short-
term use in humans is safe.
Summary
In this article, we examined the intimate and mecha-
nistic relationship between cell death and proinﬂammatory
signaling. Intriguingly, key components of cell death
signaling pathways, such as caspase and death receptor
activation, are also implicated in proinﬂammatory
signaling. Over the past decade, our knowledge of cell death
and proinﬂammatory signaling in NASH has increased.
However, the precise dominant molecular and cellular
mechanisms still remain relatively obscure. Very recently,
apoptosis by death receptors has been revised in terms
of its role in proinﬂammatory signaling. A better under-
standing of the interplay between cell death andinﬂammation may answer why some patients with steatosis
advance to steatohepatitis and may enable us to halt the
disease progression.References
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